Alimera Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 26, 2023 at 04:30 pm IST
Share
Alimera Sciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 23.36 million compared to USD 13.6 million a year ago. Net loss was USD 1.35 million compared to USD 5.26 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.75 a year ago.
For the nine months, sales was USD 54.45 million compared to USD 40.1 million a year ago. Net loss was USD 16.35 million compared to USD 14.33 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 2.05 a year ago.
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.